JCO3 Rec'd PCT/PTO 04 OCT 2005

#3

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV711314653US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: October 4, 2005

Signature:

Michelle Cluce

Docket No.: 60425 (72021)

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Patent Application of:

Rajagopal Bakthavatchalam et al.

Application No.: 10/539,031

Confirmation No.:

Filed: June 13, 2005

Art Unit: N/A

For:

ACID-SUBSTITUTED QUINAZOLIN-4-

YLAMINE ANALOGUES

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other

Docket No.: 60425 (72021)

material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper, hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 60425 (72021). A duplicate copy of this paper is enclosed.

Dated: October 4, 2005

Respectfully submitted,

John B. Alexander, Ph.D.

Registration No.: 48,399 EDWARDS & ANGELL, LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	10/539,031	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	June 13, 2005	
S	STATEMENT E	3Y /	APPLICANT	First Named Inventor	Rajagopal Bakthavatchalam	
				Art Unit	N/A	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	60425(72021)	

	U.S. PATENT DOCUMENTS						
Examiner	0.11-	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, When		
Initials*	Cite No. ¹	Number-Kind Code ² (if known)	MM-DD-YYYY		Relevant Passages or Relevant Figures Appear		
	AA*	US-5,420,135	05/1995	Brown et al.			
	AB*	US-5,064,833	11/1991	Ife et al.			
	AC*	US-5,939,421	08/1999	Palanki et al.			
	AD*	US-5,814,630	09/1998	Barker et al.			
	AE*	US-6,169,091-B1	01/2001	Cockerill et al.			
	AF*	US-6,174,889-B1	01/2001	Cockerill et al.			
	AG*	US-6,207,669-B1	03/2001	Cockerill et al.			
	AH*	US-6,395,733	05/2002	Arnold et al.			
	AI*	US-6,391,874-B1	05/2002	Cockerill et al.			
	AJ*	US-6,413,971	07/2002	Arnold et al.			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY					
	BA	WO-01/21596	03/29/2001			一		
	BB	WO-02/22601	03/21/2002			<u> </u>		
	ВС	EP-1,229,025	08/07/2002			厂		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	CA	Temple et al., "Synthesis of Potential Antimalarial Agents. II. 6,8-Disubstituted Pyrido[2,3-b]pyrazines," J. Med. Chem. 11:1216-1218 (1968).			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.